Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome

American Journal of Cardiology

Volumn 83, Issue 9, 1999, Pages 1364-1368

  Rossi Foulkes, Rita ^b   Roman, Mary J ^a   Rosen, Stacey E ^a   Kramer Fox, Randi ^a   Ehlers, Kathryn H ^b   O'Loughlin, John E ^b   Davis, Jessica G ^b   Devereux, Richard B ^a  

^a Dept Ofmedicinethe New York H ^*

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST;

ADOLESCENT; ANTHROPOMETRY; AORTA DISSECTION; AORTA RUPTURE; AORTA VALVE REGURGITATION; ARTICLE; CHILD; ECHOCARDIOGRAPHY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MITRAL VALVE PROLAPSE; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCOLIOSIS;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; AORTA; CALCIUM CHANNEL BLOCKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MARFAN SYNDROME; PHENOTYPE; PROSPECTIVE STUDIES;

EID: 0033136067     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00101-0     Document Type: Article

References (23)

1. Murdoch J.L., Walker B.A., Halpern B.L., Kuzma J.W., McKusick V.A. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med. 286:1972;804-808.
2. Ringer RK. Aortic rupture, plasma cholesterol, and arteriosclerosis following serpasil administration to turkeys. The Second Conference on the Use of Reserpine in Poultry Production, 1959:32-39.
3. Wheat M.W. Jr, Palmer R.F., Bartley T.D., Seelan R.C. Treatment of dissecting aneurysm of the aorta without surgery. J Thorac Cardiovasc Surg. 50:1965;364-373.
4. Halpern B.L., Char F., Murdoch J.L., Horton W.B., McKusick V.A. A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J. 129:1971;123-129.
5. Shores J., Berger K.R., Murphy E.A., Pyeritz R.E. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome. N Engl J Med. 330:1994;1335-1341.
6. Salim M.A., Alpert B.S., Ward J.C., Pyeritz R.E. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol. 74:1994;629-633.
7. Hirata K, Triposkiadis F, Bowen J, Boudoulas H, Wooley CF. The Marfan syndrome: rate of aortic root dilatation (abstr). Circulation 1989;80(suppl II):II-529.
8. Timchak DM, Challenger M, Dell R, Bierman FZ, Gersony WM. Progression of aortic root disease in pediatric Marfan's syndrome (abstr). Circulation 1991;84(suppl II):II-351.
9. Silverman D.I., Burton K.J., Gray J., Bosner M.S., Kouchoukos N.T., Roman M.J., Boxer M., Devereux R.B., Tsipouras P. Life expectancy in the Marfan syndrome. Am J Cardiol. 75:1995;157-160.
10. de Peape A, Devereux R.B., Dietz H.C., Hennekam R.C.M., Pyeritz R.E. Revised diagnostic criteria for the Marfan syndrome. Am J Med Gen. 62:1996;417-426.
11. McKusick V.A. Heritable Disorders of Connective Tissue. 4th edition. 1972;70-74 CV Mosby, St. Louis, MO.
12. Steinberg I. A simple screening test for the Marfan syndrome. Am J Roentgenol. 97:1966;118-124.
13. Walker B.A., Murdoch J.L. The wrist sign a useful physical finding in the Marfan syndrome . Arch Intern Med. 126:1970;276-277.
14. Roman M.J., Devereux R.B., Kramer-Fox R., O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol. 64:1989;507-512.
15. Roman M.J., Rosen S.E., Kramer-Fox R., Devereux R.B. Prognostic significance of the pattern of aortic root dilatation in the Marfan syndrome. J Am Coll Cardiol. 22:1993;1470-1476.
16. Roman M.J., Devereux R.B., Niles N.W., Hochreiter C., Kligfield P., Sato N., Spitzer M.C., Borer J.S. Aortic root dilatation as a cause of isolated severe aortic regurgitation. Prevalence, clinical and echocardiographic patterns, and relation to left ventricular hypertrophy and function. Ann Intern Med. 106:1987;800-807.
17. Weiss A.N., Mimbs J.W., Ludbrook P.A., Sobel B.E. Echocardiographic detection of mitral valve prolapse. Exclusion of false positive diagnosis and determination of inheritance. Circulation. 52:1975;1091-1096.
18. Markiewicz W., Stoner J., London E., Hunt S.A., Popp R.L. Mitral valve prolapse in one hundred presumably healthy young females. Circulation. 53:1976;464-473.
19. Devereux R.B., Kramer-Fox R., Shear M.K., Kligfield P., Pini R., Savage D.D. Diagnosis and classification of severity of mitral valve prolapse methodologic, biologic and prognostic considerations . Am Heart J. 113:1987;1265-1280.
20. Henry W.L., Gardin J.M., Ware J.H.L. Circulation. 62:1980;1054-1061.
21. Yin F.C.P., Brin K.P., Ting C.-T., Pyeritz R.E. Arterial hemodynamic indexes in Marfan's syndrome. Circulation. 79:1989;854-862.
22. Haouzi A., Berglund H., Pelikan P.C.D., Maurer G., Siegel R.J. Heterogeneous aortic response to acute â-adrenergic blockade in Marfan syndrome. Am Heart J. 133:1997;60-63.
23. Bouthier J.D., DeLuca N., Safar M.E., Simon A.C. Cardiac hypertrophy and arterial distensibility in essential hypertension. Am Heart J. 109:1985;1345-1352.